{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:31:21Z","timestamp":1792042281071,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We have been developing an angiotensin II vaccine for hypertension. We conducted a placebo-controlled dose escalation study to investigate the safety, tolerability, and immunological responses of this angiotensin II vaccine (AGMG0201). AGMG0201 was administered to participants with mild to moderate hypertension between 18 and 79 years of age. Twelve patients each were enrolled in the low-dose and high-dose groups. Within each group, subjects were randomly assigned to receive either the active study drug or a placebo at a ratio of 3:1. Each participant received a single intramuscular injection, followed by a second injection 30 days later, and was monitored for 360 days after the second dose. The results showed that most treatment-related adverse events were classified as mild or moderate in severity, including pain and erythema at the injection site. Anti-angiotensin II antibodies were observed in the AGMG0201 patients, especially in the high-dose group. Overall, AGMG0201 was well tolerated.<\/jats:p>","DOI":"10.1038\/s41440-021-00755-6","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T01:08:22Z","timestamp":1634432902000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Brief report on a phase I\/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension"],"prefix":"10.1038","volume":"45","author":[{"given":"Hironori","family":"Nakagami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishihama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Daikyoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieka","family":"Sasakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1042\/CS20030381","volume":"107","author":"MJ Brown","year":"2004","unstructured":"Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond). 2004;107:167\u201373.","journal-title":"Clin Sci (Lond)"},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","volume":"25","author":"PM Amb\u00fchl","year":"2007","unstructured":"Amb\u00fchl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63\u201372.","journal-title":"J Hypertens"},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-2125.2003.01926.x","volume":"56","author":"MR Downham","year":"2003","unstructured":"Downham MR, Auton TR, Rosul A, Sharp HL, Sj\u00f6str\u00f6m L, Rushton A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharm. 2003;56:505\u201312.","journal-title":"Br J Clin Pharm"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"9218531","DOI":"10.1155\/2019\/9218531","volume":"2019","author":"T Azegami","year":"2019","unstructured":"Azegami T, Itoh H. Vaccine development against the renin-angiotensin system for the treatment of hypertension. Int J Hypertens. 2019;2019:9218531.","journal-title":"Int J Hypertens"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","volume":"371","author":"AC Tissot","year":"2008","unstructured":"Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371:821\u20137.","journal-title":"Lancet"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"e60493","DOI":"10.1371\/journal.pone.0060493","volume":"8","author":"F Nakagami","year":"2013","unstructured":"Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS One. 2013;8:e60493.","journal-title":"PLoS One"},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.114.04534","volume":"66","author":"H Koriyama","year":"2015","unstructured":"Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, et al. Long-term reduction of high blood pressure by angiotensin ii dna vaccine in spontaneously hypertensive rats. Hypertension. 2015;66:167\u201374.","journal-title":"Hypertension"},{"key":"755_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep43920","volume":"7","author":"R Watanabe","year":"2017","unstructured":"Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci Rep. 2017;7:43920.","journal-title":"Sci Rep"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1161\/STROKEAHA.116.016269","volume":"48","author":"K Wakayama","year":"2017","unstructured":"Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress. Stroke. 2017;48:1362\u20138.","journal-title":"Stroke"},{"key":"755_CR10","first-page":"1","volume":"8","author":"H Nakagami","year":"2021","unstructured":"Nakagami H, Hayashi H, Shimamura M, Rakugi H, Morishita R. Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertens Res. 2021;8:1\u20137.","journal-title":"Hypertens Res"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00755-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T09:07:24Z","timestamp":1639386444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00755-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]},"assertion":[{"value":"29 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The Department of Health Development and Medicine is an endowed department supported by AnGes, Daicel, and FunPep and collaborated with these companies. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boehringer, Fancl, Rohto, and FunPep. R.M. is a stockholder of AnGes and Funpep, and honoraria from Anges. H.N. is a scientific advisor of Funpep. T.I., Y.D., C.D., T.K., Y.S., K.S., A.M., and E. Y are employees and stockholders of AnGes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Bellberry Human Research Ethics Committee (HREC), which was founded by the National Health and Medical Research Council and operates in accordance with its National Statement on Ethical Conduct in Human Research. The protocol has been summarized, and detailed information has been found in trials registered on ANZCTR (ACTRN12617001192370).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}